• J D Maass, S Gottschlich, T Goeroegh, B M Lippert, and J A Werner.
• Department of Otorhinolaryngology, Head and Neck Surgery, University of Kiel, Germany.
• Anticancer Res. 1997 Jul 1; 17 (4B): 2873-4.

Backgroundp53-mutations are of major importance in the development of human malignancies and occur frequently in head and neck cancer. The detection of serum p53-antibodies has been performed for a number of different cancers. For head and neck cancer though, the occurrence of serum p53-antibodies has not been determined so far.Materials And MethodsA set of 82 sera from patients with squamous cell carcinomas of the head and neck were screened for circulating antibodies against p53 with ELISA.ResultsOf 82 patients 22% (n = 18) demonstrated p53-antibodies in their sera; the specificity for malignancy was 100%.ConclusionsAs far as we know, this is the first study to reveal p53-antibodies in the sera of patients with SCCHN. The high incidence of positivity for p53-antibodies in this subset of cancer patients may give additional help in the diagnosis of this often disfiguring disease.

13 keywords...

hide…